BioStem Technologies (BSEM) vs Cel-Sci (CVM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioStem Technologies (BSEM) has outperformed Cel-Sci (CVM) over the past year, losing 50.5% versus a loss of 79.1%. Over five years, BSEM leads with a +70.7% price change compared with -99.3% for CVM. BioStem Technologies is the larger company by market cap ($44.3 million vs $39.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BSEM | CVM |
|---|---|---|
| Share price | $2.37 | $2.24 |
| Market cap | $44.25M | $39.40M |
| 1-day change | -0.84% | +5.16% |
| YTD return | -37.27% | -59.51% |
| 1-year return | -50.52% | -79.12% |
| 5-year return | +70.71% | -99.32% |
| P/E ratio (TTM) | 2.69 | — |
| Forward P/E | 8.17 | — |
| EPS (TTM) | $0.88 | $-1.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $10.39 |
| 52-week low | $2.25 | $0.89 |
| Distance from 52-week high | -71.79% | -78.44% |
| Average volume | 120.39K | 241.50K |
| Shares outstanding | 18.67M | 17.59M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BSEM has outperformed CVM by 28.6 percentage points over the past year.
BSEM vs CVM FAQ
Which is bigger, BioStem Technologies or Cel-Sci?
BioStem Technologies (BSEM) is larger, with a market capitalization of $44.25M compared with $39.40M for Cel-Sci (CVM).
Which stock has performed better over the past year, BSEM or CVM?
BSEM returned -50.52% over the past 12 months, compared with -79.12% for CVM (price return, excluding dividends). Past performance does not predict future results.
Are BioStem Technologies and Cel-Sci in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.